SS Innovations International Inc. (NASDAQ: SSII), a developer of surgical robotic technologies, has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, effective August 3, 2026. The appointment adds public-company financial and capital markets expertise as the company accelerates global commercialization of its SSi Mantra robotic surgical platform and advances preparations for U.S. Food and Drug Administration review.
Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised over $100 million during her career. She joins SS Innovations after serving as CFO at Vicarious Surgical, another robotic surgical technology developer, where she led financial and operational initiatives to reduce cash burn and strengthen the balance sheet. Her background aligns with SS Innovations' strategic focus on financial discipline and growth.
The leadership strengthening comes as SS Innovations continues pursuing FDA clearance for the SSi Mantra system while expanding internationally. The company recently graduated the inaugural class of its SS International Centre for Robotics Surgery (SSICRS) cardiac robotic surgery training program, which welcomed 33 healthcare professionals from seven countries. This underscores SS Innovations' emphasis on surgeon education alongside technology deployment, a critical factor for adoption in new markets.
For business and technology leaders, the appointment signals SS Innovations' commitment to navigating the complex regulatory and financial landscape of surgical robotics. The SSi Mantra system, if approved, could compete in the global robotic surgery market, which is dominated by Intuitive Surgical's da Vinci system. The company's focus on training and global expansion suggests a strategy to build a comprehensive ecosystem around its technology, potentially creating new opportunities for hospitals and surgeons seeking alternatives.
The news also highlights the growing importance of financial expertise in medtech companies as they scale. Romano's experience in capital markets and cash management could be crucial as SS Innovations funds its regulatory efforts and international growth. Investors should note that the company's progress in FDA clearance and training programs will be key milestones to watch.
For more information on SS Innovations, visit the company's newsroom at https://nnw.fm/SSII. Additional details on the SSi Mantra system and FDA review are available at https://nnw.fm/yY4UM.
